With significant liabilities managed by bad actors willing to enrich themselves at the expense of minority $HROW shareholders, we are short Harrow and think its stock is going lower. (7/x) full report

$HROW burns cash from operations and relies on external financing for survival. We think Harrow did not disclose to investors the existence of a DOJ investigation because it would have compromised Harrow’s ability to raise capital. (6/x)

Despite $HROW bullish comments about Iheezo, we expect the first branded ocular anesthetic in 14 years to have a tough time becoming a successful growth story. Iheezo’s compound was initially approved by the FDA in 1955 (~68 years ago) and faces established competition (5/x)

Despite $HROW claim that sales of the FDA-approved Novartis drugs are an exciting growth opportunity, our research showed that these drugs have suffered from a massive decline in Rx unit fulfillments due to competition from alternative branded and generic drugs. (4/x

In Aug 2022, Eyepoint received a DOJ subpoena seeking the production of documents related to sales, marketing, and promotional practices related to Dexycu. $HROW did not disclose this subpoena to investors despite being the responsible party for Dexycu sales & marketing (2/x

June' 22, $HROW received a FDA Warning Letter for false and misleading marketing claims. In August 2022 Harrow received a FDA Form 483 inspection report which cited unsanitary conditions and drug quality issues. A few months later, the company issued a nationwide FDA recall(3/

Bonitas is Short Harrow Health ($HROW). Harrow sells prescription eye drugs in the United States. U.S. DOJ Investigation, FDA Hurricane: Regulatory Meeting, Recall, Inspection, Warning Letter; Weak Novartis Drug Sales (1/x)

We are short $FREY. Full report and disclosure at https://t.co/tsiFkW3bYd